View the basic IMLFF stock chart on Yahoo Finance. Change the date range, chart type and compare INMED PHARMACEUTICALS INC against other. InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and. InMed Pharmaceuticals Inc. stock price, stock quotes and financial overviews from MarketWatch.
Pharmaceuticals ) InMed Inc. (IMLFF
Sign up for free penny stock alerts and watchlist. Please read our Disclaimer. InMed Pharmaceuticals was incorporated in the year The company has its headquarters in Vancouver, Canada with the variety of treatments having cannabis as the major platform. The company deals with the targeted therapy with the intent of modification of the cause of the disease in certain patients suffering from EB Simplex and the treatment of the major symptoms of the EB problem.
These diseases are handled with the aim of reduced pain, itching, healing and providing an antimicrobial approach. INM has an impact on the underlying disease with the increased production of the keratins proteins in the skin area. The research for INM is under progress for treating the problems like dermatology, pain, inflammation, arthritis, cancer and other chronic diseases.
The company is working on the concept of development of 3-D human skin models of EB for evaluation of the drug efficiency of its medications. The company had its former name as Cannabis Technologies Inc. This along with Tetrahydrocannabinol is the compound found in cannabis plant which is used to craft medicines. The company is a pre-clinical stage biopharma group specializing in the new therapies introduced through intensive research along with the innovative drug delivery systems.
The company is gaining a strong name in the medical industry. Market Potential - The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than , have been blinded by the disease.
InMed's management team has well over a century of combined experience in the biopharmaceutical space. Together, the professionals comprising this team are guiding InMed into exciting opportunities in the cannabis-pharma sector.
Vancouver , Advanced Tissues Science Inc. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTECanada's Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs. Sazzad Hossain has more than 20 years of academic and industrial experience in new drug discovery, natural health product development.
He was Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada's prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases.
C, where was Associate Director of Pharmacology and led pharmacology teams targeting pain, inflammation and cardiovascular diseases. He was associate professor of pharmacology at Federal University of Minas Gerais, Brazil between He is the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences.
His previous position was Associate Medical Director at GW Pharmaceuticals, a UK-based Pharmaceutical Company specializing in the development of cannabinoid based prescription medicines.
In this role and others at GW Pharmaceuticals, Dr. Mancini has been an executive with several biotech companies, overseeing a wide range of drug development activities. While at QLT, Ms. Mancini has led the data analysis and assimilation, writing, submission and subsequent defense of drug submissions to regulatory agencies around the world, leading to several drug approvals and label extensions.
Mancini holds a Master of Science degree from the University of Toronto. NetworkNewsWire Lexington Ave. NetworkNewsWire is a moderator of this board.
Please see disclaimer on the NetworkNewsWire website: InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
InMed Pharmaceuticals is currently developing two products in its drug pipeline: Epidermolysis Bullosa EB is group of inherited connective tissue diseases that share a common manifestation of extremely fragile skin that blisters or tears easily from friction or trauma.
Internal organs and bodily systems can also be affected by EB. It is a result in a defect of anchoring between the dermis and epidermis cause most frequently by the absence of certain keratins or, proteins in the skin.
EB is an orphan disease with no currently approved treatments and has a significant unmet medical need. INM will potentially be the first therapy designed and developed specifically to modulate disease activity and to alleviate symptoms in EB.
INM includes multiple cannabinoids as the active ingredients:. INM Glaucoma is a group of eye disorders which result in damage of the optic nerve. The damage is most often caused by an abnormally high pressure in the eye and is one of the leading causes of blindness in the developed world.
INM will be the first ever glaucoma treatment developed that is a multi-target, multi-mechanism of action therapy, utilizing multiple cannabinoids for optimal efficacy. The cannabinoids in INM have been selected to reduce the elevated intra-ocular pressure IOP in the affected eyes and provide neuroprotection for the retinal ganglion cells RGCs and other optic nerve tissues.
INM is designed as a topical formulation to be administered directly to the eye. The formulation that has been designed by InMed is a proprietary polymer-based formulation to facilitate absorption of the cannabinoids into the eye while also being well tolerated by the patients. We envision a once-a-day application, at bedtime, to deliver effective dose levels of INM There are three general types of cannabinoids: Before the s, it was often speculated that cannabinoids produced their effects through nonspecific interaction with cell membranes, instead of interacting with specific receptors.
The discovery of the first cannabinoid receptors in the s helped to clarify their role. These receptors are common in animals, and have been found in mammals, birds, fish and reptiles.
There are currently two known types of cannabinoid receptors, called CB1 and CB2. CB1 receptors are found primarily in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus.
They are also found in the cerebellum and in both male and female reproductive systems. CB1 receptors are essentially absent in the medulla oblongata, the part of the brain that is responsible for respiratory and cardiovascular functions. Thus, there is not a risk of respiratory or cardiovascular failure as there is with many other drugs. CB1 receptors appear to be responsible for the euphoric and anticonvulsive effects of cannabis.
CB2 receptors are almost exclusively found in the immune system, with the greatest density in the spleen. CB2 receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis. In addition, minor variations in each receptor have been identified.
There is some indication that other receptors exist, but none have been confirmed. Cannabinoids bind reversibly and stereo-selectively to the cannabinoid receptors. The affinity of an individual cannabinoid to each receptor determines the effect of that cannabinoid. Cannabinoids that bind more selectively to certain receptors are more desirable for medical usage.
Herbal cannabinoids are nearly insoluble in water but soluble in lipids, alcohols and other non-polar organic solvents. All herbal cannabinoids are derived from their respective 2-carboxylic acids 2-COOH by decarboxylation that is, catalyzed by heat, light, or alkaline conditions. Herbal cannabinoids occur naturally only in the cannabis plant, and are concentrated in a viscous resin that is produced in glandular structures known as trichomes.
In addition to cannabinoids, the resin is rich in terpenes, which are largely responsible for the odor of the cannabis plant. There are over ninety known herbal cannabinoids.
Other common cannabinoids include:. THC is the primary psychoactive component of the plant. Medically, it appears to mediate pain and to be neuroprotective.
Its effects are perceived to be more cerebral. It may decrease the rate of THC clearance from the body, perhaps by interfering with the metabolism of THC in the liver.
InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of. Stock analysis for InMed Pharmaceuticals Inc (IMLFF:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company. InMed Pharmaceuticals (OTCQX:IMLFF) is a pre-clinical stage, fully-integrated cannabis company. Like most cannabis-derived pharma.